KYMERA THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
KYMERA THERAPEUTICS, INC. (KYMR) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 51.65 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-03
- KYMERA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 51.65M shares, a 15.68% increase year-over-year.
- KYMERA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 51.43M shares, a 14.89% increase year-over-year.
- KYMERA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 50.71M shares, a 145.27% increase year-over-year.
- KYMERA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 45.09M shares, a 2151.53% increase year-over-year.
- KYMERA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 47.99M shares, a 176.60% increase from fiscal 2020.
- KYMERA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 17.35M shares, a 921.45% increase from fiscal 2019.
- KYMERA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 1.70M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 51.65M shares 10-Q · filed 2022-05-03 | 51.54M shares derived: average of 2 quarters · filed 2022-05-03 | 51.27M shares derived: average of 3 quarters · filed 2022-05-03 | 49.72M shares derived: average of 4 quarters · filed 2022-05-03 |
| 2021-12-31 | 51.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 51.07M shares derived: average of 2 quarters · filed 2022-02-24 | 49.08M shares derived: average of 3 quarters · filed 2022-02-24 | 47.99M shares 10-K · filed 2022-02-24 |
| 2021-09-30 | 50.71M shares 10-Q · filed 2021-11-10 | 47.90M shares derived: average of 2 quarters · filed 2021-11-10 | 46.84M shares 10-Q · filed 2021-11-10 | 46.31M shares derived: average of 4 quarters · filed 2022-05-03 |
| 2021-06-30 | 45.09M shares 10-Q · filed 2021-08-06 | 44.87M shares 10-Q · filed 2021-08-06 | 44.84M shares derived: average of 3 quarters · filed 2022-05-03 | 38.80M shares derived: average of 4 quarters · filed 2022-05-03 |
| 2021-03-31 | 44.65M shares 10-Q · filed 2022-05-03 | 44.71M shares derived: average of 2 quarters · filed 2022-05-03 | 36.70M shares derived: average of 3 quarters · filed 2022-05-03 | 28.02M shares derived: average of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | 44.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 32.72M shares derived: average of 2 quarters · filed 2022-02-24 | 22.48M shares derived: average of 3 quarters · filed 2022-02-24 | 17.35M shares 10-K · filed 2022-02-24 |
| 2020-09-30 | 20.68M shares 10-Q · filed 2021-11-10 | 11.34M shares derived: average of 2 quarters · filed 2021-11-10 | 8.21M shares 10-Q · filed 2021-11-10 | 6.63M shares derived: average of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | 2.00M shares 10-Q · filed 2021-08-06 | 1.98M shares 10-Q · filed 2021-08-06 | 1.94M shares derived: average of 3 quarters · filed 2022-02-24 | 1.89M shares derived: average of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | 1.95M shares 10-Q · filed 2021-05-06 | 1.92M shares derived: average of 2 quarters · filed 2022-02-24 | 1.86M shares derived: average of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | 1.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 1.81M shares derived: average of 2 quarters · filed 2022-02-24 | 1.70M shares 10-K · filed 2022-02-24 | |
| 2019-09-30 | 1.75M shares 10-Q · filed 2020-11-05 | 1.64M shares 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |